Calculus Capital Limited / Stargrove Pictures Limited UK Creative Content EIS Fund

Hardman & Co

Why invest

Positives

  • Strategy: To invest in a portfolio of unquoted media companies that will generate meaningful IP.

Issues

  • Time to invest: The target time to invest of 15 months is longer than for some other EIS funds.

The Investment Manager

Positives

  • Team: One of the longest standing managers in the VCT/EIS area, Calculus has a highly experienced and stable team.

Issues

  • Past performance: While Calculus has a substantial and credible record from investing in other sectors, this is a new area for the team. However, the addition of Stargrove brings sector experience.

Nuts & bolts

  • Offer period: Closing dates are quarterly on last Fridays of October, January, April and June.
  • Diversification: The aim is to invest in at least six companies.
  • Valuation: Investors will receive valuations twice a year. Industry guidelines will be used, with two auditors examining the figures.

Specific issues

  • Fees: Mixture of direct fees and charged via the investee companies.
  • Performance fee: 20% on gains over a hurdle rate of 1.2x total capital invested.

Risks

  • Risk mitigation: Although a new sector for the Manager, Calculus will use its established investment processes and has brought in a specialist advisor in Stargrove.
  • Target return: Overall, the strategy is medium-risk relative to other EIS/VCT products, with the target capital return of 2.0x towards the top end of what we’d expect for that risk category.

DOWNLOAD THE FULL REPORT

Share on:

Latest Company News

Genflow Biosciences reports early findings from SIRT6 gene therapy study

Genflow Biosciences reports early findings from its SIRT6 gene therapy study in older dogs, with further monitoring planned over...

Ilika CEO to discuss battery gigafactory development at Barcelona industry forum

Ilika CEO Graeme Purdy is set to speak at the December 2026 Barcelona battery gigafactory forum, bringing the company's...

Investors demand clear returns as AI spending comes under scrutiny

Investors are demanding clearer returns from AI spending as technology shares face pressure, with corporate earnings, data centre investment...

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

itim Group targets retail AI market with new platform launch

ITIM Group is targeting the retail AI market with itimAIQ, a new platform designed to automate operations, improve efficiency...

Drax sets date for 2026 Capital Markets Day and trading update

Drax Group will host its Capital Markets Day on 23 November 2026, providing investors and analysts with a management...

    Search